Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03934567 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Feb 29, 2024 to Jan 29, 2025 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 96 to confirmed 87 · Completion date: Sep 30, 2024 to Oct 30, 2025 · 1 morev12 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 96 to confirmed 87
    • Completion date: Sep 30, 2024 to Oct 30, 2025
    • Site details revised at 26 of 26 sites
  2. Primary completion date: Jun 30, 2023 to Feb 29, 2024 Completion date: Jun 30, 2023 to Sep 30, 2024v11 Show 1 more changeShow less
    • Completion date: Jun 30, 2023 to Sep 30, 2024
  3. Re-verified, no change to tracked fieldsv10
  4. Study sites: 24 to 26v9
  5. Site details revised at 1 of 24 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site details revised at 1 of 24 sitesv7
  2. Study sites revised (24)v6 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (24)v5 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 23 to 24 · Start date changed from estimate of Feb 28, 2020 to Apr 22, 2020v4 Show 2 more changesShow less
    • Study sites: 23 to 24
    • Start date changed from estimate of Feb 28, 2020 to Apr 22, 2020
  5. Study sites: 0 to 23 Primary and study completion dates: Apr 1, 2023 to Jun 30, 2023 · Start date: Jan 31, 2020 to Feb 28, 2020v3 Show 2 more changesShow less
    • Primary and study completion dates: Apr 1, 2023 to Jun 30, 2023
    • Start date: Jan 31, 2020 to Feb 28, 2020
  6. Start date: Dec 1, 2019 to Jan 31, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)
Trial Details
NCT Number NCT03934567
Lead Sponsor Xynomic Pharmaceuticals, Inc.
Conditions Lymphoma, Follicular
Enrollment 87 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov